rVA576 (Coversin) Long Term Safety and Efficacy Surveillance Study

Summary

Long term management of patients with complement related diseases including Paroxysmal Nocturnal Haemoglobinuria and Atypical Haemolytic Uraemic Syndrome

Timeline

Start

2017-03-13

Primary completion

2020-08-29

Completion

2020-08-29

Outcome

Outcome not reported

Stopped (Business): “The early termination of this study is a business decision, Akari have made the decision to close their global Phase III PNH program. The decision was not related to any efficacy, safety or clinical concerns regarding Coversin/rVA576.”

Drugs

Indications